# DAWN-303: HCP commentary report

> 58 verified statements (25 from clinicians verified by NPI or staff page) from 15 commentary sources · 5 findings · updated Oct 29, 2026

## Report

- Trial: A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma (DAWN-303)
- NCT ID: NCT07522073
- Registry: https://clinicaltrials.gov/study/NCT07522073
- Sponsor: Incyte Corporation
- Phase: Phase 3
- Status: Recruiting
- Version: v1.0.0, edition 1
- Accepted: 2026-10-29
- Last checked: 2026-10-29
- Release hash: db81cc77d496cbba8d14a9cd38d602bf6432c675cca0e5bf5d7e3761fd71421c

## Counts

- HCP commentary sources screened: 43
- Sources cited by verified statements: 15
- Verified statements: 58
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 25
- Findings: 5
- People found in screened sources: 11
- Voices cited: 11
- Cited voices identity-verified: 9
- Organisational or shared accounts (not counted as people): 2

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

DAWN-303 tests whether adding INCB161734 to first-line chemotherapy improves outcomes in untreated KRAS G12D-mutated metastatic pancreatic cancer. A podcast guest who reports involvement in INCB161734’s phase 1 development frames future add-on use as conditional. Speakers welcome response activity, while gastrointestinal tolerability draws concern from a social-media account whose identity and clinical role are not established in the sources reviewed for this edition. How to combine and sequence treatments remains an open question in a presentation.

## Open Medical Affairs question

How should Medical Affairs discuss early response enthusiasm, GI burden and timely testing without implying proven survival benefit, a preferred backbone or established maintenance practice?

Raised by the leading finding. The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. Selectivity-based safety confidence is qualified by a specific GI-toxicity concern
- F2. Response enthusiasm supports further evaluation, not comparative efficacy conclusions
- F3. The proposed future is a conditional add-on strategy, with chemotherapy withdrawal tied to chemotherapy toxicity
- F4. Molecular information must arrive before the frontline decision to create a meaningful trial option
- F5. Frontline intensification is not the only decision: fitness, preferences and supportive care remain consequential

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding.

| Finding | Statements | Passages | Sources | Named voices | Counterview | Limitations |
| --- | ---: | ---: | ---: | ---: | --- | ---: |
| F1 | 11 | 8 | 6 | 6 | recorded | 3 |
| F2 | 10 | 10 | 9 | 8 | recorded | 5 |
| F3 | 10 | 7 | 2 | 2 | none recorded | 3 |
| F4 | 15 | 9 | 2 | 2 | none recorded | 3 |
| F5 | 7 | 4 | 1 | 1 | none recorded | 3 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Passages supporting | Passages giving context | Sources by kind | Feeds the Medical Affairs question |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- | --- |
| F1 | 5 | 0 | 1 | 5 | 0 | 11 | 0 | 5 posts and articles, 1 podcast or video | yes |
| F2 | 6 | 0 | 1 | 2 | 1 | 12 | 0 | 8 posts and articles, 1 podcast or video | yes |
| F3 | 5 | 1 | 0 | 2 | 2 | 13 | 0 | 2 podcasts and video | yes |
| F4 | 11 | 1 | 0 | 0 | 3 | 15 | 0 | 2 podcasts and video | yes |
| F5 | 5 | 0 | 0 | 0 | 2 | 8 | 0 | 1 podcast or video | yes |

### Trial dimensions

- Primary endpoint: Overall Survival (OS): no finding draws on it directly
- Primary endpoint: Progression-free survival (PFS) by BICR: F1 (1 shared claims), F2 (1 shared claims)
- Primary endpoint: Objective Response by BICR: F1 (5 shared claims), F2 (7 shared claims)
- Secondary endpoints: F1 (2 shared claims), F2 (2 shared claims), F3 (1 shared claims)
- Population and setting: F4 (4 shared claims)
- The comparison: F1 (6 shared claims), F2 (6 shared claims), F3 (4 shared claims)
- Safety and tolerability: F1 (10 shared claims), F2 (4 shared claims), F3 (2 shared claims)
- Design and conduct: F3 (3 shared claims), F4 (1 shared claims)

## Sample findings

Paraphrased; the full report links each statement to its source.

### F3. The proposed future is a conditional add-on strategy, with chemotherapy withdrawal tied to chemotherapy toxicity

A podcast interview addresses whether DAWN-303 needs a treatment arm using INCB161734 alone.

The guest reports involvement in INCB161734’s phase 1 development.

The rationale for omitting a monotherapy arm is the guest’s explanation, not an independently documented protocol instruction.

Source: podcast, 2026-09-23.

### F4. Molecular information must arrive before the frontline decision to create a meaningful trial option

A YouTube presentation asks how treatment options might differ if a KRAS G12D result were available before initial chemotherapy.

The presentation does not identify who asks this question.

The discussion does not establish any individual patient’s eligibility for DAWN-303.

Source: YouTube video, 2026-07-14.

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 5 | Titles free |
| Detailed analysis | 6 sections | Paid |
| Verified statements with short source quotes and links | 58 | Paid |
| Trial aspects mapped | 12 | Free |
| Sources with links | 15 | Counts free |
| Speaker attribution for cited voices | 11 | Paid |

## Trial aspects

11 discussed · 1 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Overall Survival (OS) | no commentary found | 0 | 0 |
| Primary endpoint: Progression-free survival (PFS) by BICR | discussed | 1 | 1 |
| Primary endpoint: Objective Response by BICR | discussed | 7 | 6 |
| Secondary endpoints | discussed | 3 | 3 |
| Population and setting | discussed | 4 | 2 |
| The comparison | discussed | 12 | 8 |
| Safety and tolerability | discussed | 11 | 6 |
| Design and conduct | discussed | 5 | 2 |
| Timely molecular work-up and access to an upfront trial choice | discussed | 14 | 1 |
| Conditional frontline placement, maintenance and unresolved sequencing | discussed | 7 | 3 |
| Response benchmarks and the strength of inference | discussed | 10 | 9 |
| Fitness, preferences and the option not to intensify treatment | discussed | 7 | 1 |

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

## Sources

| Channel | Screened | Cited |
| --- | ---: | ---: |
| X threads | 32 | 11 |
| Bluesky threads | 8 | 1 |
| LinkedIn posts | 1 | 1 |
| Podcasts | 1 | 1 |
| YouTube | 1 | 1 |

- Screened window: 2026-01-09 to 2026-10-26
- Cited window: 2026-01-09 to 2026-10-26
- Retrieved: 2026-10-28

Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma (DAWN-303)
- Registry: NCT07522073 (https://clinicaltrials.gov/study/NCT07522073)
- Study IDs: INCB161734-303
- Sponsor: Incyte Corporation
- Collaborators: Qiagen Manchester Ltd
- Design: Phase 3 · interventional, randomized, parallel, phase3
- Status: Recruiting
- Enrollment: 588 (estimated)
- Start: 2026-04-09 (actual)
- Primary completion: 2028-09-15 (estimated)
- Primary endpoint: Overall Survival (OS) (Up to approximately 3 years)
- Primary endpoint: Progression-free survival (PFS) by BICR (Up to approximately 2 years)
- Primary endpoint: Objective Response by BICR (Up to approximately 2 years)
- Intervention: INCB161734 (drug)
- Intervention: Placebo (drug)
- Intervention: Investigator's choice of chemotherapy (drug)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- Not yet captured in this edition: a view on response durability with targeted therapy plus chemotherapy in pancreatic cancer.
- Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- 85 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
- This report represents the sources reviewed for this edition, not all HCPs or public discussion. Unnamed references and variant trial or drug spellings may be missed.
- Some earlier-phase discussions, several organization-authored trial announcements and part of the PeerView presentation were not fully assessed for their relevance to the frontline decision. Absence from this report is not evidence that no additional views exist.
- No exact-trial results publication or full protocol is included. Product-label documentation for the interventions is also absent; the report supports no conclusion about approval status.
- Early monotherapy, previously treated and combination findings must not be treated as outcomes in DAWN-303's previously untreated population.
- Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
- Unattributed PeerView passages may be from a named participant, but their speaker cannot be identified from the available evidence. They are not additional independent voices.
- Repeated posts, reposts and quoted earlier posts do not establish independent assessments or consensus. Publication and post dates do not establish session dates, readout dates or changes of mind.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, accepted 2026-10-29: current edition

Last checked for new commentary 2026-10-29. No corrections. Versions follow semver: a new or changed finding is a minor version, more evidence without a material change is a patch.

## Offer

- Size: Focused (58 verified statements)
- Current edition: $750. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of weekly updates: $1,300
- 6 months of weekly updates: $1,900
- 12 months of weekly updates: $2,600
- Optional identity linkages (12-month updates only, product updates-12-identities; speakers are named and described in every report): NPI and other verified IDs at $15 per identity-verified person in the edition at purchase (9 now), at most $750; people verified later in the term at no charge
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/dawn-303-nct07522073
- Agents: POST https://www.erudio.com/api/orders with {"report": "dawn-303-nct07522073", "product": "edition" | "updates-3" | "updates-6" | "updates-12" | "updates-12-identities", "buyer_email": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user (and a pay_url your own MPP or x402 payment client can pay over HTTP 402, when offered), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=dawn-303-07522073

## Cite

Erudio Health. DAWN-303 (NCT07522073): HCP commentary report. Edition 1, v1.0.0. Accepted Oct 29, 2026. https://www.erudio.com/reports/dawn-303-nct07522073

## Machine access

- JSON: https://www.erudio.com/reports/dawn-303-nct07522073.json
- Markdown: https://www.erudio.com/reports/dawn-303-nct07522073.md
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "dawn-303-07522073"}`